Company
Argenx
Argenx has 18 drugs tracked on RxWires: 1 post-market, 3 in Phase 3, 1 in Phase 2/3, 6 in Phase 2, 1 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod | Post-Market | Myasthenia Gravis Crisis |
| Efgartigimod PH20 SC | Phase 3 | Graves' Disease |
| Empasiprubart | Phase 3 | Multifocal Motor Neuropathy (MMN) |
| Adimanebart IV | Phase 3 | Congenital Myasthenic Syndrome |
| Efgartigimod IV or Efgartigimod PH20 SC | Phase 2/3 | Generalized Myasthenia Gravis |
| Efgartigimod Alfa-Fcab | Phase 2 | Guillain-Barre Syndrome |
| efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis |
| ARGX-121 | Phase 2 | Immunoglobulin A Nephropathy (IgAN) |
| ARGX-117 | Phase 2 | Delayed Graft Function |
| Efgartigimod Alfa | Phase 2 | Optic Neuritis |
| ARGX-110 | Phase 1/2 | Leukemia, Myeloid, Acute |
| Cusatuzumab | Phase 1 | Leukemia, Myeloid, Acute |
| ARGX-113 | Phase 1 | Healthy Volunteers |
| ARGX-213 | Phase 1 | Healthy Volunteers |
| Efgartigimod PH20 SC via PFS | Phase 1 | Healthy Volunteer |
| ARGX-113 with rHuPH20 | Phase 1 | Healthy Volunteers |
| efgartigimod PH20 SC as a prefilled syringe presentation | Phase 1 | Bioequivalence |
Latest
Follow Argenx on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.